Premium
Photodynamic therapy for treatment of malignant cutaneous lesions
Author(s) -
Waldow Stephen M.,
Lobraico Rocco V.,
Kohler Irmgard K.,
Wallk Silas,
Fritts Helen T.
Publication year - 1987
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.1900070602
Subject(s) - photodynamic therapy , hematoporphyrin , medicine , erythema , photosensitizer , edema , dermatology , necrosis , basal cell , carcinoma , pathology , surgery , photochemistry , chemistry , organic chemistry
Photodynamic therapy, employing either hematoporphyrin derivative or dihematoporphyrin ether as the photosensitizer and an argon‐pumped tunable dye laser as the activating light source, was used to treat ten patients who had primary or recurrent basal or squamous cell carcinoma or infiltrating ductal cell carcinoma lesions metastatic to the skin. Of the 155 sites that were treated, various degrees of edema, erythema, and necrosis, sometimes accompanied by blistering, were evident in all areas within 24 to 48 hours of light treatment. While our follow‐up periods are short, four patients are free of disease at eight months or more posttreatment, two patients have had recurrent and/or persistent disease within four months, and four patients died within nine months from metastatic disease or unrelated disorders. Continued investigation into the use of photodynamic therapy for treatment of malignant lesions appears warranted, based on these preliminary clinical results.